Ionis Pharmaceuticals (IONS) Amortization of Deferred Charges (2013 - 2026)

Ionis Pharmaceuticals' Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 43.06% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $7.6 million (up 14.25% YoY), while the FY2025 annual figure was $6.9 million, up 3.26% from the prior year.
• Amortization of Deferred Charges was $2.3 million for Q1 2026 at Ionis Pharmaceuticals, up from $2.0 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.3 million in Q1 2026 to a low of $1.3 million in Q4 2022.
• Historically, Amortization of Deferred Charges has averaged $1.6 million across 5 years, with a median of $1.7 million in 2025.
• Biggest YoY gain for Amortization of Deferred Charges was 56.16% in 2022; the steepest drop was 3.3% in 2022.
• A 5-year view of Amortization of Deferred Charges shows it stood at $1.3 million in 2022, then gained by 24.36% to $1.7 million in 2023, then rose by 0.6% to $1.7 million in 2024, then climbed by 17.56% to $2.0 million in 2025, then gained by 19.36% to $2.3 million in 2026.
• The last three Amortization of Deferred Charges figures came in at $2.3 million (Q1 2026), $2.0 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.